Concept of complications of reproductive aging in women for anti-aging therapy. Literature review




quality of life, reproductive aging, menopausal hormone therapy


Modern mankind, through the development of medicine and using its scientifically grounded innovations has learned to prolong human life. In Ukraine as in the whole world there is a tendency to increase in life expectancy. Since aging is a natural physiological process, a person from time immemorial has been preoccupied with the search for the so-called “Philosophy Stone” is a substance that prevents aging.

This article analyzes data from scientific publications on modern aspects of the problems associated with aging of the female body. It has been proven that aging and anti-aging processes substantiate the individualization of modern approaches to the correction of pre- and perimenopause complications. The general strategy for maintaining of women’s health in peri- and postmenopause according to the International Menopause Society includes menopausal hormone therapy, taking into accounts the therapy goals and individual risk factors. Despite all the desire to give a modern definition of aging, it is currently not possible, therefore in this literature review an attempt is made to analyze the known strategies of premature aging to develop the potential for prolonging active life.

In any case, the doctor needs to correlate the benefits and risks of menopausal hormone therapy, taking into account individual risk factors and select appropriate rehabilitation methods aimed at “improving the female face” of the classic image of old age. Since the role of estrogen deficiency in the formation of perimenopausal complications and especially premature aging, is not questioned, anti-aging strategies should be considered a pathogenetically justified method of treating vasomotor, psychosomatic symptoms and sleep disorders, as well as a method of preventing metabolic syndrome. It should be remembered that hormone therapy has a number of limitations and contraindications, which is an incentive for every doctor to contribute to prolongation of the active and healthy life of women 40+ and 50+ years old. Creation of a conceptual model for overcoming the complications of reproductive aging and especially cardiovascular events, osteoporosis, cerebrovascular pathology based on the identification of risk factors will allow to develop the protective anti-aging therapy not only to prolong a woman's life, but also to improve its quality

Author Biographies

Z. M. Dubossarska, FPE, SE “Dnipro Medical Academy of the MoH of Ukraine”, Dnipro

MD, professor, Department of Family Medicine

Y. O. Dubossarska, FPE, SE “Dnipro Medical Academy of the MoH of Ukraine”, Dnipro

MD, professor, head of the Obstetrics, Gynecology and Perinatology Department

L. P. Grek, FPE, SE “Dnipro Medical Academy of the MoH of Ukraine”, Dnipro

MD, associate professor, head of the Obstetrics, Gynecology and Perinatology Department

V. V. Radchenko, FPE, SE “Dnipro Medical Academy of the MoH of Ukraine”, Dnipro

PhD, associate professor, head of the Obstetrics, Gynecology and Perinatology Department


  1. Yureneva, S.V., Ilina, L.M., Zelenko, Z.H. “Reproductive aging of women and endothelial dysfunction.” Status Pratsens 20.6 (2015): 45–52.
  2. Perk, J., De Backer, G., Gohlke, H., et al. “European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).” Eur Heart J 33/13 (2012): 1635–1701.
  3. Nichols, M., Townsend, N., Luengo-Fernandez, R., et al. European Cardiovascular Disease Statistics 2012. University of Oxford (2012): 126 p.
  4. Wilmot, A.K., et al. “Coronary Heart Disease Mortality Declines in the United States From 1979 Through 2011: Evidence for Stagnation in Young Adults, Especially Women.” Circulation 132.11 (2015): 997–1002. DOI: 10.1161/CIRCULATIONAHA.115.015293
  5. Harlow, S.D., Gass, M., Hall, J.E., et al. “Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging.” Menopause 19 (2012): 387–95.
  6. de Villiers, T.J., et al. “Global consensus statement on menopausal hormone therapy.” Climacteric 16.2 (2013): 203–4. DOI: 10.3109/13697137.2013.771520
  7. Yureneva, C.M., Ilina, L.M., Smetnik, V.P. “Aging of the female reproductive system: from theory to clinical practice.” Obstetrics and Gynecology 3 (2014): 21–7.
  8. Thurston, R.C., Sutton-Tyrrell, K., Everson-Rose, S.A., et al. “Hot flashes and subclinical cardiovascular disease: findings from the Study of Women’s Health Across the Nation Heart Study.” Circulation 118 (2008): 1234–40.
  9. Thurston, R.C., Kuller, L.H., Edmundowicz, D., Matthews, K.A. “History of hot flashes and aortic calcification among postmenopausal women.” Menopause 17 (2010): 256–61.
  10. Thurston, R.C., Samar, R., Khoudary, E.I., et al. “Vasomotor symptoms and insulin resistance in the Study of Women’s Health Across the Nation.” J Clin Endocrinol Metab 97 (2012): 3487–94.
  11. Shurpiak, S.A. “The effectiveness and safety of MHT depends on the type, route of administration of estrogen and the type of progesterone. Analysis of clinical research data and international recommendations.” Reproductive endocrinology 38.6 (2017): 72–8.
  12. Smetnik, V.P. “Estrogen therapy regimens in menopause.” Obstetrics and Gynecology 2 (2013): 25–30
  13. Dubossarska, Z.M., ed. Тheory and practice of endocrine gynecology. Dnipro. Lira (2010): 398-418.
  14. North American Menopause Society. “Estrogen and progestogen use in postmenopausal women: 2010 position state- ment of the North American Menopause Society.” Menopause 17 (2010): 242–55.
  15. Butenko, G.M. “Age-related changes as a prerequisite for the occurrence of pathology.” Women's Health 5 (2002): 10–13.
  16. Dubossarska, Y.O. Pathophysiology of menopause in women with disrupted reproductive systems in history, the strategy of hormone replacement therapy. Thesis for MD degree. Kyiv (2006): 372 p.
  17. Smetnik, V.P., Kulakov, V.I., eds. Guide to menopause. Moscow. MIA (2001): 685 р.
  18. Rajendran, P., et al. “The Vascular Endothelium and Human Diseases.” Int J Biol Sci 9.10 (2013): 1057–69. DOI: 10.7150/ijbs.7502
  19. Matsuzawa, Y., et al. “Treating coronary disease and the impact of endothelial dysfunction.” Prog Cardiovasc Dis 57.5 (2015): 431–42. DOI: 10.1016/j.pcad.2014.10.004
  20. Phillips, S.A., Guazzi, M. “The vasculature in cardiovascular diseases: will the vasculature tell us what the future holds?” Prog Cardiovasc Dis 57.5 (2015): 407–8. DOI: 10.1016/j. pcad.2014.12.004
  21. Gevorkyan, M.A. “Experience in the use of hormone therapy in menopausal disorders.” Pharmacy 117.2 (2006).
  22. Pines, А., Sturdee, D.W., MacLennan, A.H. “Quality of life and the role of hormone therapy during menopause.” Woman’s Health 2 (2014): 32–5.
  23. Kalashnikova, M.F., Kakhturia, Y.B., Melnichenko, G.A., Sych, Y.P. “Using the properties of the gestagen component of hormone replacement therapy in patients with endocrinopathies.” Russian Medical Journal 8.11 (2000): 16–9.
  24. Dubossarskaya, Z.M. “Conceptual model of the need to overcome climacteric disorders.” Women’s Health 132.6 (2018): 109–12.
  25. Santen, R.J., Allred, D.C., Ardoin, S.P., et al. “Postmenopausal hormone therapy: An Endocrine Society scientific statement.” J Clin Endocrinol Metab 9 Suppl 1 (2010): S1–66.
  26. Dubossarska, Z.M., Grek, L.P. “Сoncept of the treatment of the climacteric period.” Collect of scientific works of Association of obstetrician-gynecologists оf Ukraine 44.2 (2019): 51–8.
  27. Radzinskiy, V.E., Dobretsova, T.A. “Menopause as a mechanism of female aging. Phytoestrogens – reconnaissance by battle.” StatusPraesens 25.2 (2015): 51–8.
  28. Dubossarskaya, Z.M., Dubossarskaya, Y.A. “Problems of reproductive aging of women and the need for protective anti-aging therapy.” Medical aspects of women health 7–8 (2019): 5–9.
  29. Harman, D. “The biologic clock: the mitochondria?” J Am Geriart Soc 20 (1972): 145–7.
  30. Beckman, K.B., Ames, B.N. “Mitochondrial aging: open questions.” Ann N-Y Acad Sci 854.1 (1998): 118–27.
  31. Lyubarova, I.B., Tikhonovskaya, O.A., Alifirova, V.M. “Features of the clinical course of climacteric syndrome and a method for correcting vegetative manifestations in women with chronic cerebral ischemia.” Russian Bulletin of obstetricians and gynecologists 8.3 (2008): 81–4.
  32. de Villіers, T., Tatarchuk, T.F., Dubossarska, Y.O., et al. “National consensus on the management of patients in menopause.” Reproductive endocrinology 27.1 (2016): 1–15.
  33. Gasanova, S.K., Zaidieva, Y.Z., Gus, A.I. “The effectiveness of low-dose continuous hormone therapy in postmenopausal women.” Obstetrics and gynecology 4 (2007): 59–61.
  34. Arefjeva, M. “The use of Femoston in menopausal disorders and concomitant diseases.” Medical aspects of women's health 1.3 (2008): 56–8.
  35. Executive Committee of the International Society for Menopause. “Guidelines for hormone replacement therapy for women during menopause.” Climacteric 7 (2004): 8–11.
  36. Isaeva, A.S., Volkov, V.I. “Statins and women's health: effects on the cardiovascular and reproductive systems.” Medical aspects of women health 7–8 (2017): 53–7.
  37. Schoenaker, D.A., Jackson, C.A., Rowlands, J.V., Mishra, GD. “Socioeconomic position, lifestyle factors and age at natural menopause: a sys – tematic review and meta-analyses of studies across six continents.” Int J Epidemiol 43 (2014): 1542–62.
  38. Reed, S.D., Lampe, J.W., Qu, C., et al. “Premenopausal vasomotor symptoms in an ethnically diverse population.” Menopause 21 (2014): 153–8. DOI: 10.1097/GME.0b013e3182952228
  39. Col, N.F., Guthrie, J.R., Politi, M., et al. “Duration of vasomotor symptoms in middle-aged women: a longitudinal study.” Menopause 16 (2009): 453–7.
  40. Avis, N.E., Crawford, S.L., Green, R.“Vasomotor Symptoms Across the Menopause Transition: Differences Among Women.” Obstet Gynecol Clin North Am 45.4 (2018): 629–40. DOI: 10.1016/j.ogc.2018.07.005
  41. Santoro, N., Epperson, C.N., Mathews, S.B. “Menopausal symptoms and their management.” Endocrinol Metab Clin North Am 44.3 (2015): 497–515. DOI: 10.1016/j.ecl.2015.05.001
  42. Smith, R.L., Gallicchio, L., Miller, S.R., et al. “Risk Factors for Extended Duration and Timing of Peak Severity of Hot Flashes.” PLoS One 11.5 (2016). DOI: 10.1371/journal.pone.0155079
  43. Pines, A. “Postmenopausal hormone therapy and coronary artery atherosclerosis.” Climacteric 15.1 (2012): 96–7.
  44. Thurston, R.C., El Khoudary, S.R., Tepper, P.G., et al. “Trajectories of Vasomotor Symptoms and Carotid Intima Media Thickness in the Study of Women’s Health Across the Nation.” Stroke 47.1 (2016): 12–7.
  45. Thurston, R.C., Chang, Y., Mancuso, P., Matthews, K.A. “Adipokines, adiposity, and vasomotor symptoms during the menopause transition: findings from the Study of Women’s Health Across the Nation.” Fertil Steril 100.3 (2013): 793–800.
  46. Thurston, R.C., Christie, I.C., Matthews, K.A. “Hot flashes and cardiac vagal control during women’s daily lives.” Menopause 19.4 (2012): 406–12.
  47. Boggia, J., Thys, T., Hansen, T.W., et al. “Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women.” Hypertension 57.3 (2011): 397–405. DOI: 10.1161/HYPERTENSIONAHA.110.156828
  48. Sliwinski, J.R., Johnson, A.K., Elkins, G.R. “Memory decline in peri- and post-menopausal women: the potential of mind-body medicine to improve cognitive performance.” Integr Med Insights 9 (2014): 17–23. DOI: 10.4137/IMI.S15682
  49. Reed, S.D., Lampe, J.W., Qu, C., et al. “Premenopausal vasomotor symptoms in an ethnically diverse population.” Menopause 21 (2014): 153–8. DOI: 10.1097/GME.0b013e3182952228
  50. Karlamangla, A.S., Lachman, M.E., Han, W., et al. “Evidence for Cognitive Aging in Midlife Women: Study of Women’s Health Across the Nation.” PLoS ONE 12.1 (2017). DOI: 10.1371/journal.pone.0169008
  51. Mitchell, E.S., Woods, N.F. “Cognitive symptoms during the menopausal transition and early postmenopause.” Climacteric 14 (2011): 252–61.
  52. Drogos, L.L., Rubin, L.H., Geller, S.E., et al. “Objective cognitive performance is related to subjective memory complaints in midlife women with moderate to severe vasomotor symptoms.” Menopause 20 (2013): 1236–42. DOI: 10,1097/GME.0b013e318291f5a6
  53. Epperson, C.N., Amin, Z., Ruparel, K., et al. “Interactive effects of estrogen and serotonin on brain activation during working memory and affective processing in menopausal women.” Psychoneuroendocrinology 37.3 (2011): 372–82. DOI: 10,1016/j. psyneuen.2011.07.007
  54. Espeland, M.A., Shumaker, S.A., Leng, I., et al. “Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years.” JAMA Intern Med 173 (2013): 1429. DOI: 10,1001/jamainternmed.2013.7727
  55. Henderso, V.W., St John, J.A., Hodis, H.N., et al. “Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis.” Neurology 87 (2016): 699–708. DOI: 10.1212/WNL.0000000000002980
  56. Allen, R.H., Cwiak, C.A., Kaunitz, A.M. “Contraception in women over 40 years of age.” CMAJ Can Med Assoc J 185.7 (2013): 565–73.
  57. Buhling, K.J., Daniels, B.V. The use of complementary and alternative medicine by women transitioning through menopause in Germany: results of survey of women aged 45–60 years.” Complement Ther Med 22.1 (2014): 94–8.
  58. US Endocrinology Society. “Treatment of menopausal symptoms. US Endocrinology Society Clinical Practice Guide.” Reproductive endocrinology 26.6 (2015): 86–93.




How to Cite

Dubossarska, Z. M., Dubossarska, Y. O., Grek, L. P., & Radchenko, V. V. (2020). Concept of complications of reproductive aging in women for anti-aging therapy. Literature review. REPRODUCTIVE ENDOCRINOLOGY, (54), 32–38.



Management of menopause